Revolutionizing Early Detection
QuickStick is a breakthrough Point of Care (POCT) blood screening platform delivering fast, affordable, and accessible early detection active surveillance.
Millions of people know they should get screened, but don’t.
Millions delay or avoid routine screenings due to:
-
- Cost barriers ($50–$500 per test)
- Time constraints and clinic access
- Fear and inconvenience
The Result?
Late detection, higher costs, and preventable mortality.
QuickStick is a self-administered, all-in-one blood screening kit designed to remove the biggest barriers.
- No clinic visits
- Easy self-administration
- Rapid screening insight
- Radically lower cost
A $45.6B Market is Shifting to the Home
- 3.5M men in the U.S. living with prostate cancer
- 9M–12M screenings annually
- At-home testing market → $45.6B by 2031
- Growing at a CAGR of 10.5% 2022-2031
Massive demand.
Underserved market.
Clear entry point.
QuickStick makes early detection simple enough for everyone and scalable enough for the world.
Chris Nelson Founder and CEO, Prostate Cancer Survivor
Chris is a proven entrepreneur who has successfully built and exited several businesses in the digital, wireless, and customer support sectors. Being a cancer survivor and an entrepreneur was the impetus to create a prostate cancer support group, and has informed his approach in developing QuickStick.
“People are surprised to learn that prostate cancer screening can be done with a simple blood test; there’s almost never a need for an invasive physical exam anymore. Screening for prostate cancer significantly reduces the likelihood of death from prostate cancer.”
- Dr. Preston C Sprenkle
Chair of the NCCN Panel for Prostate Cancer Early Detection, Yale Cancer Center/Smilow Cancer Hospital
Disclaimer – This is not an endorsement
Revolutionazing healthcare by developing a user-friendly, at-home blood screening kit that provides rapid results.